Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yurong Zou

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Medicinal Chemistry|April 23, 2026
Rational Design and Optimization of Highly Selective CSF1R Inhibitors for the Treatment of Acute Liver InjuryXue Yuan, Kongjun Liu, Yurong Zou, et al.
Journal of Chemical Information and Modeling|January 23, 2024
Local Scaffold Diversity-Contributed Generator for Discovering Potential NLRP3 InhibitorsWeichen Bo, Yangqin Duan, Yurong Zou, et al.
Journal of Medicinal Chemistry|August 21, 2024
Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1<i>H</i>-benzo[<i>d</i>]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the "Clamp" StrategyPeng Wang, Yongting Yuan, Tao Yang, et al.
Journal of Medicinal Chemistry|January 10, 2025
Design, Synthesis, and Pharmacodynamic Evaluation of Highly Selective PARP1 Inhibitors with Brain PenetranceTao Guo, Yongting Yuan, Yurong Zou, et al.
Journal of Medicinal Chemistry|August 22, 2024
Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and PeritonitisZhiyuan Fu, Yangqin Duan, Heying Pei, et al.
Acta Pharmaceutica Sinica. B|July 23, 2025
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injuryYong Chen, Xue Yuan, Wei Yan, et al.
Journal of Medicinal Chemistry|June 18, 2025
Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 InhibitorsTao Guo, Yongting Yuan, Ziyan Ma, et al.
Bioorganic Chemistry|January 26, 2023
Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitorsYong Guo, Yurong Zou, Yong Chen, et al.
Journal of Medicinal Chemistry|December 20, 2023
Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of MalignanciesKongjun Liu, Xue Yuan, Tao Yang, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual ScreeningDexin Deng, Yingxue Yang, Yurong Zou, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Medicinal Chemistry|April 23, 2026
Rational Design and Optimization of Highly Selective CSF1R Inhibitors for the Treatment of Acute Liver InjuryXue Yuan, Kongjun Liu, Yurong Zou, et al.
Journal of Chemical Information and Modeling|January 23, 2024
Local Scaffold Diversity-Contributed Generator for Discovering Potential NLRP3 InhibitorsWeichen Bo, Yangqin Duan, Yurong Zou, et al.
Journal of Medicinal Chemistry|August 21, 2024
Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1<i>H</i>-benzo[<i>d</i>]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the "Clamp" StrategyPeng Wang, Yongting Yuan, Tao Yang, et al.
Journal of Medicinal Chemistry|January 10, 2025
Design, Synthesis, and Pharmacodynamic Evaluation of Highly Selective PARP1 Inhibitors with Brain PenetranceTao Guo, Yongting Yuan, Yurong Zou, et al.
Journal of Medicinal Chemistry|August 22, 2024
Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and PeritonitisZhiyuan Fu, Yangqin Duan, Heying Pei, et al.
Acta Pharmaceutica Sinica. B|July 23, 2025
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injuryYong Chen, Xue Yuan, Wei Yan, et al.
Journal of Medicinal Chemistry|June 18, 2025
Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 InhibitorsTao Guo, Yongting Yuan, Ziyan Ma, et al.
Bioorganic Chemistry|January 26, 2023
Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitorsYong Guo, Yurong Zou, Yong Chen, et al.
Journal of Medicinal Chemistry|December 20, 2023
Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of MalignanciesKongjun Liu, Xue Yuan, Tao Yang, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual ScreeningDexin Deng, Yingxue Yang, Yurong Zou, et al.
Pageof 4